Meet ApplyKite Twin, the application assistant that learns with you
Meet your Twin, it learns with you
Your Twin learns with you
Launch week codes:30% off annual Pro20% off monthly Pro
Ends in00h00m00s
Ends in00h00m00s
Andreas Zietzer
Research Interests
Explore related searches
Articles (8)
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Aim Inflammation and calcification are hallmarks in the development of aortic valve stenosis (AVS). Ceramides mediate inflammation and calcification in the vascular tissue. The highly abundant d18:1,16:0 ceramide (C16) has been linked to increased cardiovascular mortality and obesity. In this study, we investigate the role of ceramide synthase 5 (CerS5), a critical enzyme for C16 ceramide synthesis, in the development of AVS, particularly in conjunction with a high‐fat/high‐cholesterol diet (Western diet, WD). Methods We used wild‐type (WT) and CerS5 −/− mice on WD or normal chow in a wire injury model. We measured the peak velocity to determine AVS development and performed histological analysis of the aortic valve area, immune cell infiltration (CD68 staining), and calcification ( von Kossa ). In vitro experiments involved measuring the calcification of human aortic valvular interstitial cells (VICs) and evaluating cytokine release from THP‐1 cells, a human leukemia monocytic‐like cell line, following CerS5 knockdown. Results CerS5 −/− mice showed a reduced peak velocity compared to WT only in the experiment with WD. Likewise, we observed reduced immune cell infiltration and calcification in the aortic valve of CerS5 −/− mice, but only on WD. In vitro, calcification was reduced after knockdown of CerS5 in VICs, while THP‐1 cells exhibited a decreased inflammatory response following CerS5 knockdown. Conclusion We conclude that CerS5 is an important mediator for the development of AVS in mice on WD and regulates critical pathophysiological hallmarks of AVS formation. CerS5 is therefore an interesting target for pharmacological therapy and merits further investigation.
Year:
2024
Collaborators (8)
Felix Behrens
Charité - Universitätsmedizin Berlin
Nicola Wilck
-
Jennifer Kirwan
Head of Platform
Max Delbrück Center for Molecular Medicine
Sofia K. Forslund
-
Mir-Farzin Mashreghi
Group Leader
Deutsches Rheuma-Forschungszentrum Berlin
Johannes Holle
Universitätsklinikum Tübingen
Bart Mulder
University Medical Center Groningen
Hendrik Bartolomaeus
Charité - Universitätsmedizin Berlin
Make your next move.
Prepare your application
Review drafts before you send them.